Publications by authors named "Tujia Chen"
Background: Programmed cell death protein 1 (PD-1) inhibitors are commonly used worldwide for the management of non-small cell lung cancer (NSCLC). However, it remains unclear whether pembrolizumab and sintilimab, two of the most widely used PD-1 inhibitors in China, have significantly different effects on patients with NSCLC. A multicenter retrospective cohort study was designed and implemented using propensity-score matching (PSM) analysis to compare the effectiveness and safety profiles of pembrolizumab and sintilimab in patients with advanced NSCLC undergoing comprehensive therapy.
View Article and Find Full Text PDFCost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer.
Expert Rev Pharmacoecon Outcomes Res
April 2024
Article Synopsis
- CDK4/6 inhibitors dalpiciclib and abemaciclib are approved in China as first-line treatments for advanced hormone receptor-positive and HER2-negative breast cancer in postmenopausal women.
- A Markov model was used to evaluate the cost-effectiveness of dalpiciclib combined with a non-steroidal aromatase inhibitor (NSAI) versus abemaciclib plus NSAI, using data from clinical trials.
- Dalpiciclib plus NSAI resulted in 4.27 more quality-adjusted life-years (QALYs) and had a cost-effectiveness probability of 77.42%, indicating it is a more cost-effective option for treatment compared to abemaciclib plus NSAI